Now with pos­i­tive PhI da­ta, DICE goes af­ter pub­lic of­fer­ing in search of $250M

First the pos­i­tive da­ta, then the pub­lic of­fer­ing. Akin to a host of oth­er biotechs seek­ing to re­fill their cof­fers on the heels of an op­ti­mistic da­ta read­out, San Fran­cis­co’s DICE Ther­a­peu­tics is no ex­cep­tion.

The biotech an­nounced a $250 mil­lion pub­lic of­fer­ing late Tues­day, just a mat­ter of hours af­ter it re­port­ed pos­i­tive Phase I da­ta ear­li­er that morn­ing, send­ing the biotech mo­men­tar­i­ly spik­ing to its all-time high be­fore ta­per­ing down to a 60% in­creased share price. DICE added that it plans to grant un­der­writ­ers 30 days to pur­chase up to an ad­di­tion­al $37.5 mil­lion in shares.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER